ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Danish enzymes firm Novozymes will buy Milwaukee-based EMD/Merck Crop BioScience from Merck KGaA for $275 million. Merck Crop BioScience develops natural inoculants that farmers use to improve plant health and crop yields. With operations in the U.S. and South America, the business is expected to post $60 million in 2010 sales. Novozymes already offers nitrogen-fixing inoculants for leguminous crops as part of its microbes segment, which had sales of $65 million in the first nine months of 2010. The acquisition will help Novozymes supply the so-called biofertility market, which it estimates is worth $250 million per year worldwide.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter